Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024. "HR-positive, HER2-negative is the most common type of breast cancer in the United States and we frequently need to decide whether or not adjuvant chemotherapy would be beneficial, and if so, what type of chemotherapy would be beneficial," explained Nan Chen, MD, assistant professor of internal medicine at the University of Chicago Medicine, who presented the study. Chen said that while patients with this type of breast cancer generally receive either adjuvant taxane-based regimens or taxane- and anthracycline-based regimens, there is limited data to guide the use of more intensive chemotherapy via the addition of anthracyclines.
Chen and her colleagues analyzed data from the TAILORx trial to compare outcomes of patients with stage I/II, node-negative, HR-positive, HER2-negative breast cancer who received either taxane with anthracycline/cyclophosphamide and similar regimens (T-AC) or taxane with cyclophosphamide (TC) chemotherapy after surgery. Within the trial, the OncotypeDX test was used to help predict which pat.
